Abstract. We initially cloned CARF (collaborator of ARF), as a novel ARF-binding protein by a yeast interaction screen. It also interacts with p53 directly leading to ARF-independent enhancement of p53 function and in turn undergoes a negative feedback regulation. Herein we report that i) CARF interacts with HDM2 and undergoes degradation by an HDM2-dependent proteasome pathway, and ii) it acts as a transcriptional repressor of HDM2. By overexpression and silencing studies, we demonstrated that CARF exerts a vital control on the p53-HDM2-p21WAF1 pathway that is frequently altered in cancer cells.
Introduction
The development of human cancers is frequently associated with the disruption of the two major tumor suppressor pathways governed by activities of p53 and retinoblastoma (pRB) proteins that are also closely involved in execution of cellular senescence (1) (2) (3) (4) (5) (6) (7) (8) (9) . The INK4a/ARF locus encodes two distinct tumor suppressors, a member of the INK4 cyclin-dependent kinase inhibitor family, p16 INK4A , and a completely unrelated protein, ARF (p19ARF in mouse and p14ARF in human), encoded by an alternative reading frame. These two INK4A-encoded proteins regulate cell cycle progression via the pRB and p53 pathways (10) (11) (12) (13) (14) (15) . ARF has been shown to affect both p53-and RB-mediated cell cycle arrest and apoptosis and thus, play a key role in tumor suppressor mechanisms (16) (17) (18) . It has been shown to bind to MDM2 (mouse double minute 2, called HDM2 in humans), sequester it within the nucleoli, promote its degradation and inhibit E3 ubiquitin ligase activity that is required for p53 and pRB degradation (19) (20) (21) (22) (23) (24) (25) (26) (27) . Although ARF-HDM2 binding in the nucleolus was initially identified as a key factor in regulation of p53 and pRB activities, a more complex picture emerged when certain studies showed that nucleolar localization of ARF was not essential although it may enhance the availability of ARF to inhibit HDM2 (28, 29) . Furthermore, the function of ARF did not fully correlate with MDM2 import to the nucleolus suggesting that ARF function requires other events (29) perhaps mediated by its binding partners including E2F family members, spinophilin, topoisomerase I, MdmX, Pex19p, CARF, Cyclin G1, p120 (E4F) and its homooligomers (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) .
We have previously cloned CARF as an ARF-binding protein by yeast two hybrid screening (40) . It was localized in the human chromosome 4q35, a region associated with esophageal adenocarcinoma (40, 41) . CARF was found to be expressed in most human tissue and was able to activate ARF-dependent p53 function (36, 40) . In the absence of ARF, CARF directly binds to p53 causing its stabilization and functional activation, and in turn undergoes negative feedback regulation (42) . In the present study, we addressed the molecular mechanism of CARF regulation and found that it is ubiquitinated and negatively regulated by p53 and HDM2 by proteasome-dependent degradation. To protect itself from degradation, CARF acts as a transcriptional repressor of HDM2, nullifies the antagonist effect on p53 and activate ARF-p53-HDM2-p21WAF1.
Materials and methods

Plasmids, cells, transfections and infection.
CARF was cloned into mammalian expression plasmid pcDNA3.1/V5 (Invitrogen) pMT-vector and bacterial expression plasmid pQE30 (Qiagen) to encode V5, Zn inducible CARF-myc and His-tagged proteins, respectively. Full-length HDM2 and its deletion mutants were cloned into pcDNA3.1/V5 to obtain V5-tagged HDM2 in human cells. HDM2 promoter-driven YFP expression was obtained by transfecting the cells with pU293 plasmid (kindly provided by Dr Uri Alon, Israel). Plasmid containing luciferase driven by HDM2 promoter was a kind gift from Bert Vogelstein, USA. pCMVHA-Ub encoding HA-Ub was provided by Dr Koyomi Miyazaki (AIST, Tsukuba, Japan). shRNA plasmid for HDM2 was prepared as described (43) (44) (45) . Target sequences used for HDM2-shRNA plasmids were GCCATTGCTTTTGAA GTT and GAAGCAGTAGCAGTGAATC, respectively. Human normal (TIG-1, lung fibroblast) and cancer (U2OS, osteosarcoma, HeLa, cervical carcinoma, HepG2, hepatocyte cell line, HCT116, colon carcinoma; kindly provided by B. Vogelstein, USA) cells were cultured in Dulbecco's modified Eagle's minimal essential medium supplemented with 10% fetal bovine serum. Transfections were performed using Lipofectamine™ Plus (Life Technologies, Inc.). Plasmid DNA (3 and 10 μg) was used per 80% confluent 6-and 10-cm dish, respectively. For stable transfections, pPur plasmid was co-transfected followed by selection in puromycin (2-3 μg/ml) supplemented medium. Several colonies were picked up by ring isolation. Cells were expanded and the expression of the transfected cDNAs or the target protein (in case of siRNA transfections) was analyzed by Western blotting as described below.
In vivo co-immunoprecipitation and immunodepletion. Cell lysates (400 μg protein) in 400 μl Nonidet P-40 lysis buffer were incubated at 4˚C overnight with an antibody used for immunoprecipitation. Immunocomplexes were separated by incubation with Protein-A/G Sepharose at 4˚C for 30 min, and Western blotting was performed with the indicated antibodies as described below. For immunodepletion, lysates were immunoprecipitated with the indicated antibody for three rounds of immunoprecipitation as described above. The amount of CARF left in the lysate after each round of immunoprecipitation was examined by Western blotting as described below.
In vitro and in vivo CARF and HDM2 interaction assay.
For in vitro interactions, ~125 ng of bacterially expressed His-CARF was incubated with an equal amount of GST-HDM2 and 250 ng of bovine serum albumin (BSA) in NP-40 lysis buffer. After incubation at 4˚C for 4 h, His-CARF was pulled-down with Ni-NTA agarose beads (20 μl). After six washes with NP-40 lysis buffer, the pellet was boiled in SDS sample buffer. The eluted proteins were electrophoresed through a 10% polyacrylamide gel, transferred onto a nylon membrane and blotted with anti-HDM2 and anti-His antibodies to detect HDM2 and CARF, respectively. For in vivo interactions, HepG2 cells were transfected with expression plasmids encoding V5-tagged HDM2 and its deletion mutants encoding N-terminus (N1, 204 amino acids and N2, 435 amino acids) and C-terminus (C2, 220 amino acids). HDM2 protein was immunoprecipitated with anti-V5 antibody and the co-immunoprecipitating CARF was examined by Western blotting with anti-CARF antibody. Immunoprecipitated HDM2-V5 proteins were examined by Western blotting with anti-V5 antibody.
In vivo ubiquitylation of CARF. U2OS cells were transfected with expression plasmids encoding CARF-V5, HA-Ub and HDM2 as indicated. After 48 h of transfection, cell lysates were made under denaturing conditions as described earlier (34) . CARF-V5 was immunoprecipitated with anti-V5 antibody and was detected by Western blotting with anti-V5 (Invitrogen) and anti-HA (Santa Cruz Biotech) antibodies.
Western analysis. The protein sample (10-20 μg) separated on a SDS-polyacrylamide gel was electroblotted onto a nylon membrane (Millipore) using a semidry transfer blotter (Biometra, Tokyo). Immunoblotting was performed with anti-HA tag (Santa Cruz), anti-V5 tag (Invitrogen), anti-p53 (DO-1), anti-p21 (C-19), anti-MDM2 (SMP-14, Santa Cruz) anti-BAX (BD Transduction), anti-PUMA (ProScience), anti-actin (Boehringer Mannheim) and anti-CARF (40, 42) antibodies. The immunocomplexes formed were visualized with horseradish peroxidase (HRP)-conjugated rabbit antimouse immunoglobulin G (IgG) antibody (ECL kit, Amersham Pharmacia Biotech).
Immunostaining. Cells grown on glass coverslips placed in 35-mm plastic dishes were washed with cold phosphatebuffered saline (PBS) and fixed with 4% formaldehyde for 10 min at room temperature. Fixed cells were washed with PBS and permeabilized with 0.2% Triton-X100 in PBS for 20 min. Cells were then incubated in blocking buffer (2% BSA) containing the primary antibody (either tag-specific or protein-specific as indicated in the legends of Figs. 1 an 3) for 1 h and washed extensively in PBS before incubation with the appropriate fluorochrome-conjugated secondary antibody for another 30 min. Secondary antibodies used were Alexa-488-conjugated goat anti-rabbit and anti-mouse or Alexa-594-conjugated goat anti-rabbit and anti-mouse (Molecular Probes). After six washes in PBS with 0.1% Triton X-100, cells were overlaid with a coverslip with fluoromount (Difco). The cells were examined on a Carl Zeiss microscope attached with Photomerics Synsys monochrome charge-coupled device (CCD) or on an Olympus microscope equipped with a CSU 20 spinning-disk confocal scanner (Yokogawa Electric Corporation) and ultra-high-sensitive HARP camera (Hitachi Kokusai Electric, Japan) and CSU-20 scanner (Yokogawa, Japan). The extent to which the two proteins co-localized was assessed by combining the images using Metamorph software.
CARF siRNA. 21-Nucelotide RNAs were chemically synthesized using Expedite RNA phosphoramidites and thymidine phosphoramidite. Synthetic oligonucleotides were deprotected and gel purified. Sequences of two control and two target oligos for CARF were: 5'-AAGACCGAGUCCA UGAGGCUT-3', 5'-GCCUCAUGGACUCGGUCUUUT-3' and 5'-CGGAGUACCUGAGCCAGAAUT-3', 5'-UUCUGG CUCAGGUACUCCGUT-3', respectively. For annealing of siRNAs, 20 μM of two control or target single strands were incubated in annealing buffer (100 mM potassium acetate, 30 mM HEPES-KOH at pH 7.4, 2 mM magnesium acetate) for 1 min at 90˚C followed by 1 h at 37˚C. Transfections of siRNA duplexes were carried out using Oligofectamine reagent (Life Technologies). Of the 20 μM duplexes, 1-5 μl were used per 12-well dish and were assayed after 24-48 h by immunostaining and Western blotting with anti-CARF antibody.
RT-PCR. Total RNA was isolated using TRIzol reagent (Invitrogen) and 2 μg was used to amplify 695 bp HDM2 fragment using HDM2 specific primers (sense 5'-GAGATA TGTTGTGAAAGA-3' and antisense 5'-AATGGCATT AAGGGGCAAACT-3') for 28, 33 and 38 cycles (94˚C for 5 min; 94˚C for 1 min; 48˚C for 1 min and 72˚C for 1 min). Actin was used as an internal control and was amplified using actin-specific primers (sense 5'-CTGGAACGGTGAAG GTGACA-3' and antisense 5'-CTAAGGGACTTCCTGT AACAATGCA-3'). The amplified product was resolved through 1% agarose and visualized using ethidium bromide.
Reporter assays. For HDM2 promoter assay, U20S cells were transfected with pHDM2-luc, pMTCARF-myc and pPur plasmids and the stably transfected cells were selected by puromycin (2.5 μg/ml). Cells (1x10 4 cells/well) were plated in a 24-well plate and transfected with control or CARF siRNA as described above. Sixty hours posttransfection, 100 μM ZnSO 4 was added to induce the expression of exogenous CARF-myc and the cells were assayed for luciferase 24 h later using luciferase assay kit (Promega). For p53 reporter assay, HCT116 cells (1x10 4 cells/well) grown in a 24-well plate were transfected with CARF specific or control siRNA along with pWWP-Luc (p21 promoter reporter construct). Cells were lysed after 48 h and quantitated for luciferase expression using luciferase assay reagent (Roche) and a luminometer (Wallac multi-label counter).
Results and Discussion
In light of our previous findings that CARF undergoes proteasome-mediated degradation along with p53 (42), it was anticipated that HDM2 might be involved in this process. Therefore, we examined if CARF interacts with HDM2 by performing in vitro and in vivo co-immunoprecipitation assays. As shown in Fig. 1a, HDM2 was co-immunoprecipitated with CARF from HeLa cell lysates. Co-precipitation of CARF was also observed in HDM2-immunocomplexes (data not shown). We also examined if the three proteins (CARF, HDM2 and ARF) form a complex. U2OS cells (that lack endogenous p14ARF) were transfected with expression plasmids encoding CARF-V5, p14ARF-myc and HDM2 proteins. Anti-CARF, anti-p14ARF and anti-HDM2 antibodies were used to immunodeplete the respective proteins from the lysates by three rounds of immunoprecipitation. The remaining amount of CARF-V5 left in each case was examined by Western blotting with anti-V5 antibody. As shown in Fig. 1b , CARF-V5 was depleted from the lysates not only as a consequence of CARF immunoprecipitation, but also by p14ARF and HDM2 immunoprecipitations. These data suggested that CARF interacts with p14ARF (36) and HDM2 in cells.
To further confirm the CARF-HDM2 interactions, we performed the in vitro pull down assays. Bacterially expressed His-CARF (~85 kDa) and GST-HDM2 (~115 kDa) proteins were mixed in a tube and His-CARF was pulled down with Ni-NTA agarose. Co-pulldown of GST-HDM2 was examined by Western blotting with anti-HDM2 antibody. As shown in Fig. 1c , GST-HDM2 was pulled down along with His-CARF (Fig. 1c, lane 4) . Ni-NTA, by itself, did not cause any pull down of GST-HDM2 (Fig. 1c, lane 2) . In parallel experiments using equal amounts of GST-p53 and GST-HDM2, pull down of GST-HDM2 was higher than GST-p53 (42) and data not shown. These data demonstrated that i) the interaction of CARF and HDM2 is specific and is not due to the binding of GST to His-CARF, ii) CARF may bind to HDM2 more strongly than to p53, and iii) CARF and HDM2 can bind directly and do not need other proteins. Consistent with these biochemical data on interactions of CARF and HDM2 in vivo and in vitro, we detected significant co-localization of the proteins in the nucleus (seen as yellow color in the merged photomicrographs) by fluorescence microscopy (Fig. 1d) . The data were further strengthened by in vivo co-immunoprecipitation of HDM2 and its deletion mutants with CARF. We found that CARF and its N-terminus deletion mutants (N1 and N2) could be immunoprecipitated with full-length. However, it did not precipitate with C-terminus mutant (C2) that lacked N-terminal 125 amino acids (Fig. 1e) . Of note, although the amount of immunoprecipitated C2 was manyfold more than the N1 and N2 (Fig. 1e, lower panel) , no immunoprecipitation of CARF was obtained. The data defined that the N-terminal region of HDM2 is essential for binding to CARF. Although HDM2 was able to bind to CARF directly in vitro (Fig. 1c) , the possibility that the CARF-p53 complexes (42) may be recruited to the N-terminus of HDM2 in vivo cannot be ruled out.
CARF-HDM2 binding as shown in Fig. 1 suggested that HDM2 might be involved in degradation of CARF by a proteasome-mediated pathway. We further investigated whether CARF undergoes ubiquitylation. Cells were transfected with expression plasmids encoding CARF-V5, HDM2 and HA-tagged ubiquitin and were examined for levels of CARF and CARF-V5 expression and their ubiquitination by Western blotting and immunoprecipitation by anti-CARF, V5 and HA antibodies as shown in Fig. 2 . We found: i) CARF and CARF-V5 showed a decrease when ubiquitin was overexpressed (Fig. 2a) , ii) CARF-V5 was immunoprecipitated with anti-V5 antibody and detected by Western blotting with either anti-V5 or anti-HA antibody. Ubiquitinated CARF was detected with anti-HA antibody (Fig. 2a) . As expected, ubiquitinated CARF-V5 appeared as a smear, that reacted more strongly with anti-HA antibody than with the anti-V5 antibody. Furthermore, the level of CARF was found to decrease with overexpression of HDM2 suggesting its enhanced degradation (Fig. 2a and b) . The data were also supported by a several-fold increase in the amount of ubiquitylated CARF with the treatment of cells with MG132 (Fig. 2a) . Of note, over-expression of HDM2 not only caused a reduction in CARF expression, but also in its downstream effectors, p53 and p21 (Fig. 2b) . In agreement with these findings, silencing of HDM2 by shRNA in U2OS cells resulted in an increased level of CARF in cells (Fig. 2c) . These data clearly showed that CARF undergoes HDM2-mediated ubiquitination and degradation by a proteasome pathway. Taken together with the data in Fig. 1 , we found that CARF (that was previously shown to upregulate p53 function in an ARF-dependent and -independent manner) interacts with HDM2 and gets degraded by an HDM2-mediated proteasome degradation pathway (Fig. 2d and e) . Whereas p53 is upregulated by CARF, HDM2 (p53 downstream effector and antagonist) degrades CARF in a negative feedback regulatory loop (Fig. 2e) . Degradation of CARF by HDM2 thus provides a mechanism by which this activator of p53 can be downregulated, allowing cells to progress through the cell cycle.
To understand the functional consequences of CARF-HDM2 interactions, we employed siRNA-mediated knockdown of CARF in U2OS cells. As shown in Fig. 3a , we found that the knockdown of CARF by CARF-specific siRNA caused an upregulation of HDM2 as observed by Western blotting as well as immunostaining using CARF and HDM2 specific antibodies ( Fig. 3a and b) . The data raised two new possibilities: i) CARF is essential for the proteasome degradation pathway and thus knockdown by siRNA resulted in an accumulation of HDM2 that itself gets degraded by the proteasome pathway and ii) CARF may act as a transcriptional repressor of HDM2. Based on the predominant nuclear localization of CARF and its serine-rich structure, we anticipated that it might have a role as a regulator of transcription. Hence, we performed two different assays. Cells stably expressing HDM2 promoter (3.5 kb 5' UTR containing P1 and P2 HDM2 promoter regions)-driven HDM2-YFP reporter (pU293) were made and expression of the HDM2-YFP reporter was examined following CARF-siRNA transfections. As shown in Fig. 3c , YFP reporter was highly expressed in CARF-siRNA transfected cells suggesting that normally CARF downregulates HDM2 and thus knockdown of CARF resulted in an upregulation of the HDM2. This was supported by Western analysis of HDM2 in CARF overexpressing cells that showed reduced levels of expression of both exogenous (HDM2-YFP) and endogenous (HDM2) proteins (Fig. 3d) . We also confirmed these findings by using HDM2 promoterdriven luciferase reporter in U2OS cells stably expressed with zinc inducible CARF expression vector. As shown in Fig. 3e , overexpression of CARF resulted in a reduced expression of HDM2 promoter-driven luciferase and it was abrogated by CARF silencing by siRNA. To get a final proof of transcriptional regulation of HDM2 by CARF, we performed RT-PCR analysis for HDM2 in CARF-compromised cells and detected a significant increase in HDM2 transcript level (Fig. 3f) . These results strongly implied that CARF acts as a transcriptional repressor of HDM2 and may thus account for the ARFindependent effects of CARF on p53 function as observed in our earlier studies (36, 42) .
We then examined if the transcriptional repressor function of CARF on HDM2 affects p53 function. As expected, CARF-knockdown cells showed higher amounts of HDM2 and lower levels of other p53 downstream proteins, such as, BAX, PUMA and p21WAF1 (Fig. 4a) . The result was consistent with our earlier findings that the overexpression of CARF increases p53 function. Of note, consistent with our earlier studies, the level of p53 remained unchanged in CARFknockdown cells suggesting that an increase in HDM2 level due to depletion of CARF did not initiate degradation of p53. The decrease in the level of p53 downstream proteins, p21WAF1, PUMA and BAX therefore indicate that the transactivation function of p53 was decreased by a mechanism other than HDM2-mediated p53 degradation. To further support this observation, we employed a p53-dependent promoter-based reporter assay. As shown in Fig. 4b , p53-dependent reporter activity was decreased, at least, 4-fold in CARF knockdown cells as compared to vector transfected control cells. These results demonstrated that an upregulation of HDM2 expression induced by knockdown of CARF modulated p53 functions. We earlier found that the expression of ARF and CARF are co-regulated; cells lacking ARF also lacked CARF (36) . Our present findings on the degradation of CARF by HDM2 strongly imply that whereas CARF is degraded by HDM2, the presence of ARF in the same complex may stabilize it, possibly by nucleolar sequestration. In other words, the absence of ARF makes CARF susceptible to degradation by HDM2. Collectively, the study has demonstrated that CARF has potential to control the ARF-p53-HDM2-p21WAF1 pathway at multiple points. Whereas an over-expression of CARF activates this pathway resulting in growth arrest, its simultaneous degradation by HDM2 (result of p53 activation) allows cells to enter cell cycle. To overcome this, CARF acts as a transcriptional repressor of HDM2 (Fig. 3) . It was shown that HDM2 interacts with p21WAF1 and functions as its negative regulator independent of both its p53-regulatory and ubiquitination functions (45) . Hence, the HDM2-repressor function of CARF may also affect p21WAF1, independent of p53. The only other protein known to interact with multiple members of the p53 pathway is Cyclin G1 that interacts with ARF, HDM2, and p53 in vitro and in vivo. Similar to CARF, it activates p53 function and is degraded by HDM2 through proteasome-mediated degradation (39) .
CARF was first cloned as an ARF-binding protein that activated ARF-mediated p53 function (36, 40) . In the absence of p14ARF, it was found to bind to p53 directly and resulted in its activation (42) suggesting that CARF activates the p53 pathway by its ARF-dependent and -independent p53 activation functions. Earlier studies also showed that the strong activation of p53 by CARF could be overcome, at least in part, by negative regulation of CARF by p53, possibly by degradation (42) . In the present study, we showed that CARF directly binds to HDM2 (Fig. 1) , becomes ubiquitylated in vivo and undergoes HDM2-mediated degradation (Fig. 2) . The data explained the molecular mechanism of regulation of CARF by p53 and brought in focus another level of control that CARF puts on the p53 pathway. For the first time, we demonstrate a novel feedback loop in which CARF protects itself from HDM2-mediated degradation by acting as a transcriptional repressor of HDM2 (Fig. 3) . In continuation with our earlier studies showing collaboration with ARF and p53 (36, 42) , we demonstrated herein that CARF inactivates its own-and p53-antagonist, HDM2 and thus brings to light a novel regulatory loop of the CARF-p53-HDM2-p21WAF1 pathway. Collectively, CARF, by imposing multiple regulatory checkpoints, may act as a novel key regulator of p53 pathway.
